Topic Hub
18 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 18 of 18 clinical reviews.
Semaglutide (Ozempic) 0.5-2.0 mg is being explored off-label for heart failure. Review the dosing protocol, trial evidence from SELECT and STEP-HFpEF, FDA-approved indications, and what clinicians should know.
Read clinical reviewA physician-reviewed summary of the clinical trial evidence, off-label status, GRADE ratings, and practical considerations for using semaglutide (Ozempic 0.5 to 2.0 mg) in heart failure patients.
Read clinical reviewSemaglutide (Ozempic) is not FDA-approved for heart failure, but emerging trial data in HFpEF shows measurable benefits. Learn the evidence, monitoring protocols, and safety considerations for off-label use.
Read clinical reviewA clinical review of using semaglutide (Ozempic 0.5-2.0 mg) off-label for heart failure, including trial data, safety signals, and how it compares to FDA-approved HFpEF therapies.
Read clinical reviewA physician-reviewed evidence summary on using Ozempic (semaglutide 0.5 to 2.0 mg) off-label for kidney protection, including trial data, GRADE ratings, dosing considerations, and clinical guidance.
Read clinical reviewCan Ozempic (semaglutide 0.5 to 2.0 mg) protect the kidneys? A full clinical review of the FLOW trial, off-label prescribing rationale, GRADE evidence levels, and the monitoring protocol your nephrologist should follow.
Read clinical reviewSemaglutide (Ozempic) 0.5-2.0 mg is being studied for kidney protection in CKD. Review the off-label evidence, dosing protocols, FLOW trial results, and clinical guidance for renal use.
Read clinical reviewA clinical review of semaglutide (Ozempic) for kidney protection, including FLOW trial data, off-label considerations, dosing, risks, and what the evidence actually supports.
Read clinical reviewClinical evidence review of off-label semaglutide (Ozempic 0.5-2.0 mg) for nonalcoholic steatohepatitis (NASH), including trial data, dosing, and guideline positioning.
Read clinical reviewSemaglutide (Ozempic) 0.5 to 2.0 mg is used off-label for NASH. Review the dosing protocol, key trial data, FDA status, and what clinicians should know before prescribing.
Read clinical reviewSemaglutide (Ozempic) is not FDA-approved for NASH/MASH, but clinical trial data shows histological improvement in liver fibrosis and steatohepatitis. Learn the risks, dosing, and evidence.
Read clinical reviewComplete guide to monitoring requirements when using Ozempic (semaglutide 0.5-2.0 mg) off-label for PCOS, including lab schedules, safety parameters, and clinical endpoints.
Read clinical reviewSemaglutide (Ozempic) is used off-label for PCOS to improve insulin resistance, restore ovulation, and reduce androgen levels. Learn the dosing protocol, evidence base, and what clinicians should discuss with patients.
Read clinical reviewA clinician-reviewed evidence summary of off-label semaglutide (Ozempic) for polycystic ovary syndrome (PCOS), covering trial data on weight, androgens, ovulation, and insulin resistance.
Read clinical reviewOzempic (semaglutide 0.5-2.0 mg) is FDA-approved for type 2 diabetes, not weight loss. Here's what the clinical trials show about off-label use, real risks, and how it compares to the approved weight-loss dose.
Read clinical reviewOzempic (semaglutide 0.5 to 2.0 mg) is FDA-approved for type 2 diabetes, not weight loss. This clinician-reviewed guide covers the evidence, off-label dosing protocols, risks, and how it compares to FDA-approved Wegovy for weight management.
Read clinical reviewOzempic (semaglutide 0.5-2.0 mg) is FDA-approved for type 2 diabetes but widely prescribed off-label for weight loss. Learn the evidence, proper monitoring, and clinical protocols.
Read clinical reviewA clinical evidence summary of off-label semaglutide (Ozempic 0.5 to 2.0 mg) for weight loss, including trial data, FDA status, dosing, and how it compares to on-label Wegovy.
Read clinical review